X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

IP Explained: Four key takeaways from new Bayh-Dole white paper

By Tom Wilbur  |    February 19, 2020
2020 marks the 40th anniversary of the Bayh-Dole Act being signed into law. The Bayh-Dole Act laid the foundation for effective technology transfer that modernized the U.S. economy, set a global...   Read More

Trump administration must defend and protect U.S. innovation

By Priscilla VanderVeer  |    February 6, 2020
PhRMA recently submitted comments to the Office of the United States Trade Representative (USTR)’s Special 301 Report, calling on the Trump administration to defend American biopharmaceutical...   Read More

IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy

By Tom Wilbur  |    November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...   Read More

IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act

By Tom Wilbur  |    October 9, 2019
In our last IP Explained post, we outlined how the Bayh-Dole Act laid the foundation for effective technology transfer across industries in the United States and helps foster continued medical...   Read More

IP Explained: Four things to know about the Bayh-Dole Act

By Tom Wilbur  |    September 13, 2019
Thanks in large part to strong intellectual property protections – including policies that incentivize public and private investments in research and development (R&D) – the United States is the ...   Read More

IP Explained: Understanding biopharmaceutical innovation

By Andrew Powaleny  |    July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...   Read More

IP Explained: Why IP protections are important for biologic medicines

By Tom Wilbur  |    July 18, 2019
Biologics are cutting-edge therapies that treat or cure some of the most challenging and costly diseases. These medicines are created from living organisms through highly complex manufacturing...   Read More

IP Explained: What is Section 101 and why reforms are needed

By Tom Wilbur  |    June 26, 2019
In today’s IP Explained post, we’re taking a closer look at Section 101 of the United States Patent Act and how proposed reforms could both level the playing field for innovators across all...   Read More

World Trade Month: How we can expand world-class pro-innovation standards

By Douglas Petersen  |    May 22, 2019
May is World Trade Month—a celebration of the industries that import and export goods and services around the world. The month offers a good opportunity to examine the significance of...   Read More

IP Explained: How Hatch-Waxman successfully balances affordability and innovation

By Tom Wilbur  |    May 22, 2019
For three decades, The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, has fostered innovation, spurred competition and helped the United...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates